First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B
Suárez, C., Lee, J.-L., Ziobro, M., Gafanov, R.A., Matveev, V.B., Donskov, F., Pouliot, F., Alekseev, B.Y., Wiechno, P.J., Tomczak, P., Climent, M.A., Shin, S.J., Kloss Silverman, R., Perini, R.F., Schloss, C., McDermott, D.F., Atkins, M.B.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Zugman, M., McDermott, D.F., Escudier, B., Hutson, T.E., Porta, C.G., Verzoni, E., Atkins, M.B., Rini, B.I., Pal, S.K.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Published in Annals of oncology (01.08.2020)
Published in Annals of oncology (01.08.2020)
Get full text
Journal Article
1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
McKay, R.R., Xie, W., Leucht, K., Jegede, O., Braun, D.A., Atkins, M.B., Grimm, M-O., Choueiri, T.K.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
70P Treatment patterns and overall survival (OS) in patients with advanced BRAF mutant (mt) melanoma treated with immunotherapy and targeted therapy (TT) in a real-world setting
Atkins, M.B., Julian, C., Secrest, M.H., Lee, J., Abajo, A.M., McKenna, E.
Published in Annals of oncology (01.12.2020)
Published in Annals of oncology (01.12.2020)
Get full text
Journal Article
PD-L1 expression in nonclear-cell renal cell carcinoma
Choueiri, T.K., Fay, A.P., Gray, K.P., Callea, M., Ho, T.H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., Stanton, M.L., Hodi, F.S., McDermott, D.F., Atkins, M.B., Freeman, G.J., Hirsch, M.S., Signoretti, S.
Published in Annals of oncology (01.11.2014)
Published in Annals of oncology (01.11.2014)
Get full text
Journal Article
Volume of Disease as a Predictor for Clinical Outcomes in Patients with Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Immunotherapy
Burke, A.M., Carrasquilla, M., Jean, W.C., Collins, B.T., Anaizi, A., Atkins, M.B., Gibney, G., Collins, S.P.
Published in International journal of radiation oncology, biology, physics (01.09.2019)
Published in International journal of radiation oncology, biology, physics (01.09.2019)
Get full text
Journal Article
1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J.B.A.G., Gurney, H.P., Ravilla, R., Van der Veldt, A.A.M., Beuselinck, B., Pokataev, I., Suelmann, B.B., Tuthill, M., Vaena, D., Zagouri, F., Wu, J., Liu, Y., Perini, R., Merchan, J.R., Atkins, M.B.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Huang, R., Youssef, G., Nelson, T., Wen, P., Forsyth, P., Hodi, F.S., Margolin, K.A., Algazi, A.P., Hamid, O., Lao, C.D., Ernstoff, M.S., Moschos, S.J., Atkins, M.B., Postow, M., Reardon, D.A., Grootendorst, D.J., Askelson, M., Ritchings, C., Tawbi, H.A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
971P - Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma
Regan, M.M., Atkins, M.B., Powles, T., Werner, L., Mantia, C., Yang, S., Johansen, J.L., Rao, S., Gooden, K.M., McDermott, D.F.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma
Regan, M.M., Atkins, M.B., Powles, T., Werner, L., Mantia, C., Yang, S., Johansen, J.L., Rao, S., Gooden, K.M., McDermott, D.F.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214
Regan, M., Jegede, O.A., Mantia, C., Powles, T., Werner, L., Huo, S., Del Tejo, V., Stwalley, B., Atkins, M.B., McDermott, D.F.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1039MO CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Tawbi, H.A., Forsyth, P.A., Hodi, F.S., Algazi, A., Hamid, O., Lao, C.D., Moschos, S.J., Atkins, M.B., Lewis, K., Postow, M.A., Thomas, R.P., Khushalani, N.I., Pavlick, A.C., Ernstoff, M.S., Reardon, D.A., Chung, C., Lee, C-W., Bas, T., Askelson, M., Margolin, K.A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
Lee, J-L., McDermott, D.F., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V.B., Wiechno, P., Gafanov, R., Tomczak, P., Pouliot, F., Donskov, F., Alekseev, B.Y., Shin, S.J., Bjarnason, G.A., Castellano, D., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M.B.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Tannir, N.M., Albigès, L., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Barthélémy, P., Plimack, E.R., Porta, C., George, S., Donskov, F., Atkins, M.B., Gurney, H., Kollmannsberger, C.K., Grimm, M.-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B.I., Jiang, R., Desilva, H., Fedorov, V., Lee, C.-W., Motzer, R.J.
Published in Annals of oncology (01.11.2024)
Published in Annals of oncology (01.11.2024)
Get full text
Journal Article
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J.B., Gurney, H., Ravilla, R., Van der Veldt, A., Beuselinck, B., Pokataev, I., Suelmann, B.B.M., Tuthill, M.H., Vaena, D., Zagouri, F., Wu, J., Perini, R.F., Liu, Y., Merchan, J., Atkins, M.B.
Published in Annals of oncology (02.09.2024)
Published in Annals of oncology (02.09.2024)
Get full text
Journal Article
Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
Atkins, M.B., Plimack, E.R., Puzanov, I., Fishman, M.N., McDermott, D., Cho, D.C., Vaishampayan, U., George, S., Olencki, T., Tarazi, J., Rosbrook, B., Fernandez, K., Keefe, S., Choueiri, T.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
McDermott, D.F., Lee, J-L., Bjarnason, G.A., Larkin, J., Gafanov, R., Kochenderfer, M.D., Jensen, N.V., Donskov, F., Malik, J., Poprach, A., Tykodi, S.S., Alonso-Gordoa, T., Cho, D.C., Geertsen, P.F., Climent Duran, M.A., Di Simone, C., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M.B.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone vs IPI among treatment-naïve patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Botteman, M., Shah, R., Gupte-Singh, K., Luo, L., Sabater, J., Rao, S., McDermott, D.F., Atkins, M.B., Regan, M.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article